These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17012896)

  • 1. Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults.
    Dentinger CM; Hennessy TW; Bulkow LR; Reasonover AL; Romero-Steiner S; Holder PF; de Leon PG; Carlone GM; Parks DJ; Parkinson AJ; Singleton RJ; Levine OS; Butler JC
    Hum Vaccin; 2006; 2(1):24-8. PubMed ID: 17012896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.
    Baggett HC; Hennessy TW; Bulkow L; Romero-Steiner S; Hurlburt D; Holder P; Parkinson AJ; Singleton RJ; Levine O; Carlone GM; Butler JC
    Clin Vaccine Immunol; 2006 Jun; 13(6):620-6. PubMed ID: 16760318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV.
    Arya BK; Bhattacharya SD; Sutcliffe CG; Saha MK; Bhattacharyya S; Niyogi SK; Moss WJ; Panda S; Das RS; Mallick M; Mandal S
    Vaccine; 2016 Apr; 34(19):2267-74. PubMed ID: 26988256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
    Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy.
    Southern J; McVernon J; Gelb D; Andrews N; Morris R; Crowley-Luke A; Goldblatt D; Miller E
    Clin Vaccine Immunol; 2007 Oct; 14(10):1328-33. PubMed ID: 17699835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
    Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer.
    Hamidi A; Verdijk P; Kreeftenberg H
    Hum Vaccin Immunother; 2014; 10(9):2691-6. PubMed ID: 25483504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska.
    Galil K; Singleton R; Levine OS; Fitzgerald MA; Bulkow L; Getty M; Perkins BA; Parkinson A
    J Infect Dis; 1999 Jan; 179(1):101-6. PubMed ID: 9841828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response.
    Dockrell DH; Poland GA; Steckelberg JM; Wollan PC; Strickland SR; Pomeroy C
    Vaccine; 1999 Jul; 17(22):2779-85. PubMed ID: 10438047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.